Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

3(42.9%)

Phase 2

2(28.6%)

Phase 4

2(28.6%)

7Total

Phase 1(3)

Phase 2(2)

Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT03180333Phase 1Completed

The Tolerability and Pharmacokinetics Clinical Trial of Metacavir Enteric-coated Capsules in Healthy Adult Volunteers

Role: lead

NCT03173599Phase 1Completed

The Safety and Tolerability of Metacavir Enteric-coated Capsules in Healthy Adult Volunteers

Role: lead

NCT02654158Completed

Phase IV Trial,The Efficacy and Safety Study of Fuganlin Oral Liquid in Children With Acute Upper Respiratory Infection

Role: lead

NCT02622659Phase 4Completed

The Efficacy and Safety Study of Fuganlin Oral Liquid in Children With Influenza (Acute Upper Respiratory Infection)

Role: lead

NCT03080740Phase 4Unknown

The Efficacy and Safety Study of Clindamycin Palmitate Hydrochloride Dispersible Tablet Treatment of Bacterial Vaginosis

Role: lead

NCT02877173Phase 2Unknown

A Safety/Efficacy Study of Alprostadil Liposomes for Injection to Treat Lower Extremity Arteriosclerosis Obliterans

Role: lead

NCT02965859Phase 2Unknown

The Safety and Dose-range Study of Metacavir Enteric-coated Capsules in Patients With Chronic Hepatitis B

Role: lead

NCT02889822Phase 1Completed

The Tolerability of Alprostadil Liposome for Injection in Healthy Adult Volunteers

Role: lead

All 8 trials loaded